Hoth Therapeutics Inc

NASDAQ:HOTHUnited States

NASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)

Hoth Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing a topical formulation for treating side effects from drugs used for the treatment of cancer (HT-001); a treatment for mast-cell derived cancers and anaphylaxis (HT-KIT); a treatment for traumatic brain injury and ischemic stroke (HT-TBI) and a treatment and/or prevention for Alzheimer’s or other neuroinflammatory diseases (HT-ALZ). It also has assets being developed for atopic dermatitis (also known as eczema) (BioLexa); a treatment for asthma and allergies using inhalational administration (HT-004), and a treatment for acne as well as inflammatory bowel diseases (HT-003). Its development products include HT-001, HT-KIT, HT-ALZ, and HT-TBI. Its BioLexa Platform is a proprietary, patented, drug compound platform for the treatment of eczema. The Company also has interests in certain other assets being developed by third parties including a treatment for patients with lupus.

Contact Information

Headquarters

590 Madison Avenue, 21St FloorNEW YORK, NY, United States 10022

Phone

646-756-2997

Fax

---

Executives

President, Chief Executive Officer, Director

Robb Knie

Chief Financial Officer

David Briones

Independent Director

Wayne Linsley

Independent Director

Jeff Pavell

Independent Director

David Sarnoff